Not approved — human evidence is primarily endogenous physiology
A hormone made in the thymus, an organ involved in immune function. Its activity depends on zinc.
5-minute readFull profile reviewed July 31, 2026
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Thymulin at a glance
Why people look into it, what studies found, and what is still unknown.
Why people look into it
How immune function changes with age, zinc levels, and some hormone or health conditions.
What studies found
Human studies measured naturally occurring thymulin. Correcting zinc deficiency or thyroid problems sometimes changed those levels; the studies did not give synthetic thymulin.
What is still unclear
There is no established human treatment program showing that added synthetic thymulin improves immunity or longevity. Its benefits and safety remain unknown.
About the evidence and review date
Educational information only. Evidence reviewed through July 31, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Why people research it
Each label shows how much evidence supports that question.
Endogenous thymic immune signalingEarly human evidence
Zinc-dependent thymulin activityEarly human evidence
T-cell differentiation biologyAnimal or lab research
Human immune-system treatmentNot demonstrated
Human inflammation or analgesia treatmentNot demonstrated
Human longevity or anti-agingNot demonstrated
What studies show
What the evidence supports
The research behind the answer
Human studies consistently demonstrate zinc-dependent endogenous thymulin activity and modulation by zinc and endocrine state; they do not establish administered synthetic-Thymulin efficacy.
See each finding and its sources (7)
Mechanistic rationale
Thymulin is a thymic-epithelial-cell nonapeptide whose recognized biological activity depends on binding zinc in approximately a 1:1 ratio.
The zinc-free peptide is often called serum thymic factor or FTS, while the zinc-bound active complex is called thymulin.
Assay-defined activity and zinc binding do not establish an approved medicinal product or therapeutic dose.
No established administered synthetic-Thymulin human treatment program with clinical outcomes was identified by Relay.
Direct evidence for immune benefit, inflammation reduction, longevity, analgesia, endocrine effects, or disease treatment remains unestablished.
Search results can evolve, but endogenous measurements, zinc supplementation, cell studies, animal studies, and gene-therapy analog work cannot substitute for an exact peptide-treatment trial.
Relay has not verified a clear pattern of side effects for this compound.
Evidence boundary
Human exposure is present, but the record is not detailed enough to characterize a reliable adverse-event pattern.
Missing reports do not establish safety. Findings apply to the product, route, amounts, population, comparison, and follow-up studied.
Side-effect frequency, study withdrawals, and gaps
How often side effects occurred
The available information does not reliably show how often particular side effects occur.
Evidence boundary
Under-detected or under-reported events must not be described as rare.
Why people stopped in studies
Relay has not verified which side effects led people to stop treatment in studies.
Evidence boundary
This is an evidence gap, not proof that discontinuations did not occur.
Warning information
Relay has not verified a compound-specific warning summary for this profile.
Evidence boundary
Not FDA approved; no established administered synthetic-Thymulin human treatment program or product standard identified Whether administered synthetic zinc-bound Thymulin has a reproducible pharmacologic identity, target exposure, pharmacokinetics, human safety profile, or clinical benefit without disrupting complex thymic and immune-endocrine regulation.
Emergency instructions
This profile does not contain verified, product-specific emergency instructions.
Evidence boundary
Relay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Dosing & preparation
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
Route: Route unverified · No exact human administration route established in this review
Evidence gap · Route unverified
Human research exists; dose details remain unverified
Endogenous thymulin measurements, zinc studies, and thymic extracts are not the same as a verified administered-thymulin regimen.
What would fill this gap: A primary human report identifying the peptide, zinc complex, route, amount, and schedule.
Dosing review checked Oct 20, 2026. Additional sources are available below.
Formulation & handling · Route unverified
No route-specific preparation instructions were verified. A different route or product does not supply them.
Starting dose, maintenance, and trial targets explained
Starting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
Other source records, populations, and limits · all routes
No direct study for this identity
Administered synthetic thymulin evidence
Amount in this source
A complete human regimen was not verified in this source record. See the dosing status above.
Frequency
Not established in human treatment research
Route
No verified administration route for a standardized synthetic product
Duration
Not established in the reviewed record
Population, study design, and limitations
Published human research mainly measured naturally produced thymulin before and after changes in zinc or underlying disease. It did not establish a synthetic-thymulin treatment program.
Population: No directly studied human population was verified for this identity.
Design: Human physiology and biomarker studies; no verified direct treatment study
Zinc supplementation and treatment of thyroid disease cannot be reframed as thymulin administration.
The section remains incomplete because product identity, exposure, safety, and clinical-outcome evidence are not established.
No direct primary administration source was verified for this exact identity.
Mechanisms
How it works
Thymulin is the biologically active zinc complex of the nonapeptide historically called serum thymic factor. Zinc binding produces a conformational and assay-active state associated with thymic epithelial secretion and T-cell differentiation biology. Human studies describe endogenous activity across zinc deficiency, endocrine disease, diabetes, renal disease, and other conditions; selected zinc-repletion studies increased endogenous measured activity. Laboratory research supports immune-endocrine signaling, while therapeutic concepts such as anti-inflammatory, analgesic, endocrine, and gene-delivered analog effects remain predominantly preclinical. Endogenous levels, zinc supplementation, synthetic peptide, zinc-free FTS, zinc-bound thymulin, analogs, and gene-delivery constructs must remain separate evidence records.
Why this matters
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Signals and targets
No fully validated human therapeutic receptorImmune and pituitary signaling pathways proposed in laboratory models
Proposed biological steps
Zinc-dependent thymic-hormone conformation
Thymic epithelial-cell secretion
T-cell differentiation and immune-endocrine signaling
Proposed anti-inflammatory and hypophysiotropic effects - primarily preclinical
Research reference
How mature is the evidence?
A reference for the studies, populations, and routes behind this profile.
Research depthSubstantial endogenous-physiology record
Human biomarker and zinc-intervention studies characterize endogenous thymulin; synthetic administration evidence is absent.
Why this matters
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Evidence confidenceModerate for zinc-dependent physiology
The endogenous relationship is reproducible, but therapeutic effects of synthetic thymulin remain untested.
Why this matters
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
Strongest evidenceHuman endogenous physiology and zinc-repletion studiesWhy this matters
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human evidenceHuman biomarker evidence, not synthetic-thymulin treatment evidenceWhy this matters
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
Which product or study does this describe?
Administered synthetic thymulin evidence: amounts and schedules describe this route record only.
Route studiedNo verified administration route for a standardized synthetic product
Schedules studiedNot established in human treatment research
Amounts studiedWithheld: this record provides research context without a transferable amountWhy this matters
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-lifeNot established for this exact editorial recordWhy this matters
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Route evidencePublished human research mainly measured naturally produced thymulin before and after changes in zinc or underlying disease. It did not establish a synthetic-thymulin treatment program.Why this matters
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Zinc supplementation and treatment of thyroid disease cannot be reframed as thymulin administration. The section remains incomplete because product identity, exposure, safety, and clinical-outcome evidence are not established. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study-by-study record
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
Why this matters
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Laboratory studyPeer reviewed
Interleukin 1 regulates secretion of zinc-thymulin by human thymic epithelial cells and its action on T-lymphocyte proliferation and nuclear protein kinase C
Direct synthetic Thymulin human treatment evidence
What was reported
Relay did not identify an established administered synthetic-Thymulin human treatment program with clinical outcomes.
Study administration and important limits
Study administration: Not stated in the current record.
Limitations: Search audits cannot prove that no unpublished or nonregistered exposure exists, but they prevent endogenous-hormone measurements from being presented as treatment trials.
Community
Experience reports stay separate from published evidence
Loading Community Intelligence…
Built by the community
Help strengthen the Thymulin experience record
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.
Where to go next
Keep the question moving
Move from one profile into a direct comparison, a multi-compound evidence map, or a related record.
Interleukin 1 regulates secretion of zinc-thymulin by human thymic epithelial cells and its action on T-lymphocyte proliferation and nuclear protein kinase C